Brief: Ultragenyx Q2 EPS USD -1.17

Ultragenyx Pharmaceutical

05/08/2025 21:01

Overview

Ultragenyx Q2 2025 revenue rises 13% yr/yr to $166 mln

Company reaffirms 2025 revenue guidance of $640 mln to $670 mln

Net loss for Q2 2025 was $115 mln

Outlook

Ultragenyx reaffirms 2025 revenue guidance of $640 mln to $670 mln

Company expects Crysvita revenue of $460 mln to $480 mln in 2025

Ultragenyx anticipates Dojolvi revenue of $90 mln to $100 mln in 2025

Company sees modest increase in net cash used due to timing delays

Result Drivers

CRYSVITA SALES - Crysvita revenue reached $120 mln, driven by Latin America and Türkiye product sales

DOJOLVI PERFORMANCE - Dojolvi contributed $23 mln to Q2 revenue

EVKEEZA LAUNCH - Evkeeza revenue increased to $15 mln as launch continues outside the U.S.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$1.17
Q2 Net Income
-$115 mln
Q2 Operating Expenses
$274 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $81.00, about 64.9% above its August 4 closing price of $28.46

Press Release: ID:nGNX3XgNHH

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)